Fast Five Quiz: Signs and Symptoms of Mantle Cell Lymphoma

Ann S. LaCasce, MD, MMSc


February 07, 2023

The Ann Arbor classification system is used for staging and is on the basis of lymph node involvement and the presence of extrahepatic sites.

The majority of patients (nearly 70%-80%) with MCL present with stage III or IV disease with extensive lymph node involvement. Presentation with earlier stage disease is uncommon. Patients with stage I/II disease have a limited number of lymph nodes or extranodal sites involved. Laboratory values are critical in workup but are not a component of staging.

Learn more about MCL.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.